MedTrace Logo

Tranexamic Acid in Orthopaedic Trauma Surgery

NCT02080494 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2018-07-11

No results posted yet for this study

Summary

Tranexamic acid is an antifibrinolytic drug that has been used to decrease post-operative blood loss. This study is a prospective, randomized controlled trial investigating the use of tranexamic acid in fracture surgery around the hip and knee, in which significant blood loss (\>300mL) is expected.

The hypothesis of this study is that tranexamic acid will be associated with a decrease in post-operative blood loss, as well as a decreased need for allogenic blood transfusion, in patients who have fracture surgery around the hip and knee.

Conditions

  • Blood Loss
  • Trauma
  • Fracture
  • Surgery

Interventions

DRUG

Tranexamic Acid

Sponsors & Collaborators

  • University of Tennessee

    lead OTHER

Principal Investigators

  • Dirk W Kiner, MD · UTCOM Chattanooga / Erlanger Health System

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02080494 on ClinicalTrials.gov